Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Digestive System Neuroendocrine Tumor G1 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × 64Cu-DOTATATE × Endocrine × Clear all
NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡